Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | ARG1 | P05089 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978535 | 1.00 | SLC1A2 (0.47) | SLC1A2ARG1MEN1BLMKMT2A | |
| SCHEMBL17740138 | 1.00 | SLC1A2 (0.47) | SLC1A2ARG1MEN1BLMKMT2A | |
| SCHEMBL17740136 | 1.00 | SLC1A2 (0.47) | SLC1A2ARG1MEN1BLMKMT2A | |
| SCHEMBL15571615 | 1.00 | SLC1A2 (0.47) | SLC1A2ARG1MEN1BLMKMT2A | |
| SCHEMBL2032498 | 1.00 | SLC1A2 (0.47) | SLC1A2ARG1MEN1BLMKMT2A | |
| SCHEMBL3939453 | 0.82 | SLC1A2 (0.36) | SLC1A2ARG1MEN1BLMKMT2A | |
| SCHEMBL27638808 | 0.79 | ARG1 (0.33) | SLC1A2ARG1 | |
| SCHEMBL28142406 | 0.79 | ARG1 (0.33) | SLC1A2ARG1 | |
| SCHEMBL7989737 | 0.78 | — | — | |
| SCHEMBL7993099 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470546-B1 | HEXAHYDROOXAZINOPTERIDINE COMPOUNDS FOR USE AS MTOR INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8268819-B2 | Hexahydrooxazinopterine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120178924-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2470546-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8163755-B2 | Hexahydrooxazinopterine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2011025889-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | WO | disclosed |
| US-20110053921-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178924-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | HPRT1, HCCS, NUDT1 | SLC1A2 3107/4885ARG1 2537/4885MEN1 620/4885 |
| US-20110053921-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | MTOR, RICTOR, EIF4EBP1 | SLC1A2 4108/4885ARG1 2599/4885MEN1 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.